Piper Sandler on Biogen (BIIB): 'Can Still Get Worse For The Shares'; PT Lowered to $135
Tweet Send to a Friend
Piper Sandler analyst David Amsellem lowered the price target on Biogen (NASDAQ: BIIB) to $135.00 (from $138.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
